Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity: A Comparison of Outcomes in Patients From the Virtual International Stroke Trials Archive (VISTA)

Background and Purpose— Baseline stroke severity predicts outcomes among thrombolysed patients. The baseline National Institutes of Health Stroke Scale (NIHSS) thresholds are sometimes used to select patients for thrombolysis, clinical trial enrollment, or both. Using data lodged with Virtual International Stroke Trials Archive, we compared adjusted outcomes between thrombolysed and nonthrombolysed patients enrolled in neuroprotection trials (1998–2007) to assess the influence of various levels of baseline NIHSS. Method— We assessed the association of treatment with outcome, measured across the modified Rankin scale score distribution, in patients categorized by baseline NIHSS in increments of 4. We used an age and baseline NIHSS adjusted Cochran-Mantel-Haenszel test followed by proportional odds logistic regression analysis. We report the Cochran-Mantel-Haenszel P values and estimated odds ratios (OR) for improved modified Rankin scale score distribution with treatment for patients within each baseline NIHSS category. Results— Data were available for 5817 patients (1585 thrombolysed and 4232 nonthrombolysed). Baseline severity was greater among thrombolysed than nonthrombolysed (median baseline NIHSS, 14 vs 13; P<0.05). An association of treatment with outcome was seen independently and was of similar magnitude within each of the baseline NIHSS categories 5 to 8 (P=0.04; OR, 1.25; 95% confidence interval [CI], 1.0–1.6; N=278/934 thrombolysed/nonthrombolysed), 9 to 12 (P=0.01; OR, 1.3; 95% CI, 1.1–1.6; N=404/942), 13 to 16 (P<0.05; OR, 1.6; 95% CI, 1.3–2.1; N=342/814), 17 to 20 (P<0.05; OR, 1.7; 95% CI, 1.3–2.1; N=311/736), and 21 to 24 (P<0.05; OR, 1.6; 95% CI, 1.1–2.1; N=178/466). No association was observed within baseline NIHSS categories 1 to 4 (P=0.8; OR, 1.1; 95% CI, 0.3–4.4; N=8/161) or ≥25 (P=0.08; OR, 1.1; 95% CI, 0.7–1.9; N=64/179). Conclusions— In this nonrandomized comparison, outcomes after thrombolysis were significantly better than in untreated comparators across baseline NIHSS 5 to 24. The significant association was lost only at extremes of baseline NIHSS when sample sizes were small and confidence limits were wide.

[1]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[2]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[3]  G. Azzimondi,et al.  Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment. , 1997, Stroke.

[4]  J. Mann.  tPA for acute stroke: balancing baseline imbalances. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  A. Ziegler,et al.  Age and National Institutes of Health Stroke Scale Score Within 6 Hours After Onset Are Accurate Predictors of Outcome After Cerebral Ischemia: Development and External Validation of Prognostic Models , 2003, Stroke.

[6]  Barbara Gregson,et al.  Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. , 2005, Journal of neurotrauma.

[7]  J. Grotta,et al.  NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[8]  A. Siegel,et al.  Good Outcomes in Ischemic Stroke Patients Treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms , 2006, Stroke.

[9]  J. Grotta,et al.  Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial , 2006, Stroke.

[10]  S. Pocock,et al.  Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials , 2007, Stroke.

[11]  J. Saver.  Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials , 2007, Stroke.

[12]  J. Grotta,et al.  Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics , 2007, Neurocritical care.

[13]  J. Saver,et al.  Confirmation of tPA Treatment Effect by Baseline Severity-Adjusted End Point Reanalysis of the NINDS-tPA Stroke Trials , 2007, Stroke.

[14]  J. Grotta,et al.  The Virtual International Stroke Trials Archive , 2007, Stroke.

[15]  W. Hacke,et al.  Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials , 2007, Stroke.

[16]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[17]  Gary A. Ford,et al.  Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) , 2008, Stroke.

[18]  欧洲卒中组织（ESO）执行委员会和ESO写作委员会,et al.  Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008 , 2008 .

[19]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[20]  L. Gray.  Optimising the analysis of stroke trials , 2008 .

[21]  Gerhard Nahler,et al.  Committee for Proprietary Medicinal Products (CPMP) , 2009 .

[22]  J. Gornbein,et al.  Treatment effects for which shift or binary analyses are advantageous in acute stroke trials , 2009, Neurology.

[23]  P. Bath,et al.  Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? , 2009, Stroke.

[24]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.